Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Table 4 Effect of host and HIV-1 viral factors on day 7 and 28 changes in HIV-1 plasma viral load

Variables	Categories	HIV-1 VL_0–7 (N = 30)			HIV-1 VL_0–28 (N = 22)
Variables	Categories	Mean rank	U/χ² (df)	p value	Mean rank	U/χ² (df)	p value
HBV status	HIV alone	10.00 (n = 11)	44.0	0.300	12.20 (n = 10)	33.0	0.218
HBV status	Co-infection	13.00 (n = 11)	44.0	0.300	8.80 (n = 10)	33.0	0.218
Sex	Male	12.86 (n = 7)	43.0	0.503	15.35 (n = 9)	19.0	0.020
Sex	Female	10.87 (n = 15)	43.0	0.503	8.29 (n = 11)	19.0	0.020
WHO clinical stage	Stage 1	4.25 (n = 2)	2.794 (2)	0.247	9.00 (n = 1)	0.068 (2)	0.966
	Stage 2	12.09 (n = 17)			10.56 (n = 16)
	Stage 3	13.00 (n = 3)			10.67 (n = 3)
Antiretroviral drugs	d4T + 3TC + EFV	11.00 (n = 2)	0.737 (3)	0.864	10.50 (n = 2)	3.182 (3)	0.364
	d4T + 3TC + NVP	12.83 (n = 6)			9.75 (n = 4)
	CBV + EFV	12.25 (n = 8)			13.13 (n = 8)
	CBV + NVP	10.06 (n = 8)			7.50 (n = 6)
Mutations	Present	5.75 (n = 2)	8.5	0.292	9.5 (n = 4)	26.0	0.878
Mutations	Absent	10.75 (n = 17)	8.5	0.292	10.75 (n = 16)	26.0	0.878
HIV-1 subtype	02AG	10.41 (n = 17)	24	0.410	9.5 (n = 4)	37	0.898
HIV-1 subtype	Non 02AG	13.50 (n = 4)	24	0.410	10.75 (n = 16)	37	0.898

Significant p values are in italics
U, Mann–Whitney U test; χ² (df), Kruskal–Wallis H test; Co-infection, HIV and HBV co-infection; VL _0–7 HIV-1 plasma viral load changes after 7 days of therapy; VL _0–28 HIV-1 plasma viral load changes after 28 days of therapy

ISSN: 1476-0711